DSS, INC. - 22 May 2025 Form 4 Insider Report for IMPACT BIOMEDICAL INC. (IBO)

Reporting relationship: 10%+ Owner
Issuer ticker: IBO
Reported as of: 22 May 2025
Net transaction value: -$88,006
SEC form: 4
Accepted by SEC: 06 Jan 2026, 17:25:05 UTC
Prior SEC filing: 07 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Jason Grady

Key filing fact

DSS, INC. filed Form 4 for IMPACT BIOMEDICAL INC. (IBO) on 06 Jan 2026.

Key facts

This page summarizes DSS, INC.'s Form 4 filing for IMPACT BIOMEDICAL INC. (IBO).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 06 Jan 2026, 17:25.

Change

Previous filing in this sequence was filed on 07 Apr 2025.
Current net transaction value: -$88,006.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0000771999 Primary reporting owner

DSS, INC.

Relationship: 10%+ Owner
Address: 275 WIREGRASS PKWY, HENRIETTA
Signature: /s/ Jason Grady
Signature date: 06 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IBO transaction

Common Stock

Sale

Transaction value: $63,476
Shares: -115,600
Change %: -16%
Price: $0.5491
Shares after: 590,424
Date: 22 May 2025
Ownership: Direct

IBO transaction

Common Stock

Sale

Transaction value: $24,530
Shares: -45,400
Change %: -7.7%
Price: $0.5403
Shares after: 545,024
Date: 27 May 2025
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

SEC remarks

This entity is a wholly-owned subsidiary of DSS, Inc. This amendment filing corrects an error in connection with the number of total shares of Common Stock that DSS, Inc. beneficially owns of IBO from its previously filed Form 4 on May 27, 2025. This corrected amendment includes DSS' correct beneficial ownership of IBO, which includes 545,024 shares of IBO's common stock pursuant to the Celios Asset sale.